Dianthus Therapeutics to Participate in Three Investor Conferences During September
Dianthus Therapeutics (Nasdaq: DNTH) announced participation in three September 2026 investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) announced participation in three September 2026 investor conferences. At the Wells Fargo 21st Annual Healthcare Conference on September 8, executives will hold one-on-one meetings. CEO Marino Garcia will join fireside chats at Citi's Biopharma Back to School Conference on September 9 and the Cantor Global Healthcare Conference on September 10, alongside additional one-on-one investor meetings. Webcasts of the Citi and Cantor presentations will be available through the Investors section of the Dianthus Therapeutics website.
Details
News Market Reaction – DNTH
On Sep 1, the day this news came out, DNTH closed 0.96% above the previous close.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Investor conferences
- 3 conferences
- September 2026
- Wells Fargo meeting date
- September 8, 2026
- One-on-one investor meetings
- Citi conference date
- September 9, 2026
- Fireside chat and investor meetings
- Citi fireside chat time
- 4:20 p.m. ET
- September 9, 2026
- Cantor conference date
- September 10, 2026
- Fireside chat and investor meetings
- Cantor fireside chat time
- 8:35 a.m. ET
- September 10, 2026
Historical Context
-
Agomab proposed appointing Dianthus CEO Marino Garcia to its board.
-
Dianthus reported Q2 results and clinical progress across neuromuscular programs.
-
Dianthus announced DNTH312, a bifunctional fusion protein candidate for autoimmune diseases.
-
Dianthus granted options covering 87,000 shares to six newly hired employees.
-
Dianthus granted options covering 58,000 shares to five newly hired employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in three investor conferences.
- Wells Fargo 21st Annual Healthcare Conference: Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on September 8, 2026.
- Citi's 2026 Biopharma Back to School Conference: Marino Garcia will participate in a fireside chat on Wednesday, September 9, 2026, at 4:20 p.m. ET and host one-on-one investor meetings.
- 2026 Cantor Global Healthcare Conference: Marino Garcia will participate in a fireside chat on Thursday, September 10, 2026, at 8:35 a.m. ET and host one-on-one investor meetings.
Webcasts of the presentations at the Citi and Cantor conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.